Spots Global Cancer Trial Database for relapsed acute lymphoblastic leukemia
Every month we try and update this database with for relapsed acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT00941928 | Leukemia Pediatric Cance... | Epratuzumab Fludarabine Cyclophosphamid... Mesna Infusion of NK ... Interleukin-2 | - | M.D. Anderson Cancer Center | |
| Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT04012879 | Relapsed Acute ... Refractory Acut... | CD19 CART | 18 Years - 65 Years | Chinese PLA General Hospital | |
| Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | NCT00928200 | Relapsed Acute ... Allergy to PEG ... Allergy to Nati... | Erwinase Vincristine Dexamethasone Doxorubicin Cytarabine Methotrexate Triple Intrathe... Dexrazoxane | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | NCT03349281 | Refractory Acut... Relapsed Acute ... | Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone | 16 Years - 39 Years | University of Miami | |
| Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | NCT01743807 | Relapsed Acute ... Relapsed Acute ... | GNKG168 | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Study of Children With Refractory or Relapsed ALL | NCT00187083 | Acute Lymphobla... | Topotecan, dexa... E. coli Asparag... erwinia asparag... fludarabine, me... idarubicin, eto... chemotherapy, i... | - 18 Years | St. Jude Children's Research Hospital | |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | NCT05192889 | Refractory Acut... Relapsed Acute ... | Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation | 4 Years - 30 Years | St. Jude Children's Research Hospital | |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | NCT03349281 | Refractory Acut... Relapsed Acute ... | Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone | 16 Years - 39 Years | University of Miami | |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | NCT03575325 | Lymphoid Leukem... Acute Lymphobla... Refractory Acut... Relapsed Acute ... | CPX-351 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | NCT05192889 | Refractory Acut... Relapsed Acute ... | Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation | 4 Years - 30 Years | St. Jude Children's Research Hospital | |
| Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | NCT03349281 | Refractory Acut... Relapsed Acute ... | Pevonedistat Vincristine Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Hydrocortisone | 16 Years - 39 Years | University of Miami | |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | NCT03575325 | Lymphoid Leukem... Acute Lymphobla... Refractory Acut... Relapsed Acute ... | CPX-351 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT04012879 | Relapsed Acute ... Refractory Acut... | CD19 CART | 18 Years - 65 Years | Chinese PLA General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
